Equities
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)105.50
  • Today's Change0.80 / 0.76%
  • Shares traded8.73k
  • 1 Year change-2.76%
  • Beta0.6242
Data delayed at least 15 minutes, as of Nov 22 2024 10:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

  • Revenue in SEK (TTM)1.36bn
  • Net income in SEK336.82m
  • Incorporated1990
  • Employees222.00
  • Location
    Biogaia ABKungsbroplan 3STOCKHOLM 112 27SwedenSWE
  • Phone+46 855529300
  • Fax+46 855529301
  • Websitehttps://sv.biogaia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Flerie AB100.00k-269.52m3.48bn2.00--0.8168--34,809.81-22.07-22.070.001954.590.00004----14,285.71-11.53-37.64-11.69-41.14-92,017.00-450.51-269,618.00-454.62---2.580.0002----277.025.05------
Probi AB630.39m10.88m4.00bn157.00367.452.9235.686.340.95520.955255.33120.070.40493.247.143,939,931.000.69914.640.74094.9833.1842.041.739.834.83--0.056121.421.520.7684-58.60-26.0931.01--
Swedencare AB (publ)2.47bn76.20m7.20bn559.0094.360.936118.422.910.48010.480115.5848.390.24282.268.695,087,037.000.74831.380.77271.4356.7655.343.085.101.672.420.172645.3327.4888.16-37.9620.2430.90--
BioGaia AB1.36bn336.82m10.20bn222.0031.406.5425.017.533.333.3313.4216.010.6442----6,455,538.0016.0015.4717.7316.9373.5973.3024.8527.70----0.00104.4217.4411.81-2.2511.2029.2728.10
Vimian Group AB4.08bn2.97m22.13bn1.10k8,580.012.8955.705.420.0050.0058.3214.800.34012.856.753,710,460.000.0938--0.1025--46.88--0.2758--2.182.060.2734--17.92--245.95------
Bonesupport Holding AB814.46m90.58m22.77bn131.00253.9234.88225.2027.961.361.3612.299.921.160.61385.627,756,762.0012.85-9.0814.98-11.2892.4390.2511.12-11.653.50--0.0222--79.7643.65459.44--18.39--
Bavarian Nordic A/S9.43bn1.74bn23.57bn1.61k13.401.418.822.5014.3614.3678.05136.860.44391.475.524,401,443.008.181.2110.461.4852.3853.7218.434.060.976--0.01060.00124.1469.78524.66--35.76--
Camurus AB1.69bn266.21m32.99bn249.00126.1010.60117.3219.534.454.4528.8652.920.62461.035.837,929,653.009.84-1.1311.34-1.4192.3890.0515.76-1.637.91--0.0059--79.52103.39676.63--16.29--
ALK-Abello A/S8.36bn1.22bn48.68bn2.80k43.066.7328.725.823.593.5924.4022.970.78491.296.391,906,162.0011.453.5013.844.3763.9460.6614.585.071.4732.260.09110.006.9410.6045.07--16.32--
Data as of Nov 22 2024. Currency figures normalised to Biogaia AB's reporting currency: Swedish Krona SEK

Institutional shareholders

28.49%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 20237.75m7.95%
Premier Fund Managers Ltd.as of 31 Dec 20234.31m4.42%
Teknik Innovation Norden Fonder ABas of 31 Dec 20233.00m3.08%
Tredje AP-fondenas of 31 Dec 20232.38m2.44%
Montanaro Asset Management Ltd.as of 30 Sep 20241.98m2.03%
Juno Investment Partnersas of 31 Dec 20231.98m2.03%
Handelsbanken Fonder ABas of 31 Dec 20231.94m1.99%
AMF Fonder ABas of 31 Dec 20231.86m1.91%
Allianz Global Investors GmbHas of 31 Jul 20241.38m1.41%
L�nsf�rs�kringar Fondf�rvaltning ABas of 31 Oct 20241.19m1.23%
More ▼
Data from 31 Dec 2022 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.